Publications by authors named "Moses Huang"

Claim this Profile
Q
Quality of life in patients aged 65 years and older with overactive bladder treated with mirabegron across eight European countries: Secondary analysis of BELIEVE.
Stephen Foley, Nurul Choudhury, Moses Huang, Anny Stari, Jameel Nazir

Int J Urol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vesomni improves the quality of life in men with lower urinary tract symptoms in routine clinical practice in Europe.
Jonathan Rees, Steve Foley, Moses Huang, José Rosa Arias, René Skoumal

Neurourol Urodyn· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy.
Karl-Erik Andersson, Nurul Choudhury, Jean-Nicolas Cornu, Moses Huang, Cees Korstanje

Ther Adv Urol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mirabegron improves quality-of-life, treatment satisfaction, and persistence in patients with overactive bladder: a multi-center, non-interventional, real-world, 12-month study.
Robert Freeman, Steve Foley, José Rosa Arias, Eduardo Vicente, Robert Grill, Moses Huang

Curr Med Res Opin· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies.
Andrea Tubaro, José E Batista, Victor W Nitti, Sender Herschorn, Christopher R Chapple, Moses Huang

Ther Adv Urol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.
Mike Herdman, Jameel Nazir, Zalmai Hakimi, Emad Siddiqui, Moses Huang

Patient· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study.
William Gibson, Scott MacDiarmid, Moses Huang, Emad Siddiqui, Matthias Stölzel

Eur Urol Focus· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk.
Marcus J Drake, Scott MacDiarmid, Salman Al-Shukri, Jack Barkin, Aino Fianu-Jonasson, Moses Huang

Urology· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).
Marcus J Drake, Scott MacDiarmid, Christopher R Chapple, Adil Esen, Stavros Athanasiou, Moses Huang

Int J Clin Pract· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
Scott MacDiarmid, Salman Al-Shukri, Jack Barkin, Aino Fianu-Jonasson, Philippe Grise, Moses Huang

J Urol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE).
Marcus J Drake, Christopher Chapple, Ahmet A Esen, Stavros Athanasiou, Javier Cambronero, Moses Huang

Eur Urol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial.
Jose E Batista, Heinz Kölbl, Sender Herschorn, Tomasz Rechberger, Javier Cambronero, Moses Huang

Ther Adv Urol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year.
Christopher R Chapple, Steven A Kaplan, David Mitcheson, Mary Beth Blauwet, Moses Huang

Int J Urol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reductions in overactive bladder-related incontinence from pooled analysis of phase III trials evaluating treatment with solifenacin.
Linda Cardozo, David Castro-Diaz, Marc Gittelman, Arwin Ridder, Moses Huang

Int Urogynecol J Pelvic Floor Dysfunct· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of solifenacin succinate in healthy young men.
Ronald A Smulders, Walter J Krauwinkel, Pieter J Swart, Moses Huang

J Clin Pharmacol· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis